Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Report a Problem to the Center for Biologics Evaluation & Research

Report a Problem to the Center for Biologics Evaluation & Research

                        Biological Product Deviations
          Good Tissue Practices (GTP) & Reporting
          Transfusion/Donation Fatalities
          Direct Recall Classification Program
          Human Cell & Tissue Products (HCT/P) Adverse Reaction Reporting


                        Vaccine Adverse Events Home
          Vaccines, Blood & Biologics
          Safety & Availability (Biologics)
          Report a Problem to the Center for Biologics Evaluation & Research
          Biological Product DeviationsReport a Problem to the Center for Biologics Evaluation & Research Biological Product Deviations
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    Print**Includes Human Tissue and Cellular and Tissue-Based Product (HCT/P) Deviation Reporting**

FDA requires reporting of certain deviations and unexpected events in manufacturing in accordance with 21 CFR 600.14, 606.171 or 1271.350(b).

The following manufacturers, who had control over the product when an event associated with manufacturing (deviation or unexpected event) occurred, are required to submit Biological Product Deviation (BPD) reports to the Food and Drug Administration (FDA), if the safety, purity, or potency of a distributed product may be affected:

Manufacturers of licensed biological products other than blood and blood components (licensed non‐blood) who hold the biological product license [21 CFR 600.14];
	Licensed manufacturers of blood and blood components, including Source Plasma [21 CFR 606.171];
	Unlicensed registered blood establishments [21 CFR 606.171]; and
	Transfusion services [21 CFR 606.171].Manufacturers of nonreproductive human cells, tissues, and cellular and tissue‐based products (HCT/Ps) regulated by FDA solely under section 361 of the Public Health Service Act and 21 CFR Part 1271 are required to submit HCT/P deviation reports to the FDA/Center for Biologics Evaluation and Research [21 CFR 1271.350(b)], if the deviation or unexpected event involving a distributed product is related to a Core Current Good Tissue Practice requirement [21 CFR 1271.150(b)] and related to the prevention of communicable disease transmission or HCT/P contamination.

A manufacturer is required to report to the FDA as soon as possible, but not to exceed 45 calendar days from the date of discovery of information reasonably suggesting a reportable event has occurred.

Reports should be submitted using FDA Form 3486. The report may be submitted electronically to CBER or in paper form by mail. Instructions on completing the form are available. There are links below for the list of biological product deviation reporting and HCT/P deviation reporting codes; the list of blood product codes; and the list of non-blood product codes, to include allergenics, derivatives, in-vitro diagnostics, therapeutics, vaccines, and HCT/Ps. The biological product deviation codes are used to categorize the deviation or unexpected event. The use of these codes will assist the FDA in analyzing the data submitted and streamline the trend analysis process. The product codes are used to identify the product(s) affected.

**Biological product deviations reports required by 21 CFR 600.14, 21 CFR 606.171, or 21 CFR 1271.350(b), involving a product regulated by the Center for Biologics Evaluation and Research should be submitted electronically (Electronic Submission of Biological Product Deviation Reports (eBPDR) | FDA) or sent to: sent to:**

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Avenue
WO71-G112
Silver Spring, MD 20993-0002

**Refer to CDER - Biological Product Deviations | FDAfor biological product deviations reports required by 21 CFR 600.14, involving a therapeutic product regulated by the Center for Drugs Evaluation and Research.**



**Forms & Instructions**

General Instructions for Completing the Biological Product Deviation Report (BPDR) - Form FDA 3486
	Instructions for Using the eBPDR System
	Direct Recall Classification Program
	CBER's Direct Recall Classification (DRC) program provides establishments the opportunity to electronically report recall related information directly to CBER.
	Electronic Submission of Biological Product Deviation Reports (eBPDR)
	Biological Product Deviation Guidances & Rules
	Biological Product Deviation Report**Deviation Codes**

Biological Product Deviation Reporting and HCT/P Deviation Reporting - Deviation Codes
	Biological Product Deviation Reporting and HCT/P Deviation Reporting - Non-Blood Product Codes
	Biological Product Deviation Reporting - Blood Product Codes**Reports & Publications**

Biological Product Deviation Reports Annual Summaries**Questions About Submitting a Report**

Biological Product Deviation Reporting (BPDR) CBER Contact Information
	Refer to CDER - Biological Product Deviations | FDA questions regarding reporting to CDER.

                                                                                  Content current as of:
      07/13/2023
              
              
Regulated Product(s)
		 BiologicsReport a Problem to the Center for Biologics Evaluation & Research

          
                        Biological Product Deviations
          Good Tissue Practices (GTP) & Reporting
          Transfusion/Donation Fatalities
          Direct Recall Classification Program
          Human Cell & Tissue Products (HCT/P) Adverse Reaction Reporting


                        Vaccine Adverse Events
 Subscribe for CBER Updates
                        Get e-mail updates on What’s New at CBER!
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop